Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients
The findings indicate that evaluating the financial implications of high-cost treatments requires considering not only drug prices but also analysis of total cost increase.
Authors
- M. Sumiyoshi
- Keita Sasaki (ORCID: https://orcid.org/0009-0005-5100-3863)
- Michiyo Saimura (ORCID: https://orcid.org/0000-0002-1709-3819)
- Yuko Takano (ORCID: https://orcid.org/0000-0002-3753-7683)
- Fumikata Hara (ORCID: https://orcid.org/0000-0001-8025-3494)
- Mitsuo Terada (ORCID: https://orcid.org/0000-0002-1304-2619)
- Shinsuke Sasada (ORCID: https://orcid.org/0000-0003-1623-869X)
- Kanako Saito
- Tsuguo Iwatani (ORCID: https://orcid.org/0000-0001-7162-1515)
- Tomomi Fujisawa (ORCID: https://orcid.org/0000-0002-8437-5808)
- Tadahiko Shien (ORCID: https://orcid.org/0000-0003-3202-5512)
- Hiroji Iwata
- Ryunosuke Machida (ORCID: https://orcid.org/0000-0002-3734-6203)
- Kei Koizumi
- Yoshie Kobayashi
Institutions
- Hiroshima University (JP)
- Hamamatsu University School of Medicine (JP)
- Nagoya City University (JP)
- Nagoya University Hospital (JP)
- Okayama University Hospital (JP)
- Hiroshima City Asa Citizens Hospital (JP)
- Mie University Hospital (JP)
- Breast Center (CH)
- Kitakyushu Municipal Medical Center (JP)
- Hiroshima University Hospital (JP)
- Gunma Prefectural Cardiovascular Center (JP)
- Aichi Cancer Center (JP)
- National Hospital Organization (JP)
- Gunma Children's Medical Center (JP)
- Japan Clinical Cancer Research Organization (JP)
- Kure Medical Center (JP)
- Hamamatsu Medical Center (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1093/jjco/hyae109
- Citations
- 5
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 2.09